Moderna Inc (MRNA)
132.89
+0.21
(+0.16%)
USD |
NASDAQ |
May 17, 16:00
132.77
-0.12
(-0.09%)
After-Hours: 20:00
Moderna Research and Development Expense (Annual): 4.845B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 4.845B |
December 31, 2022 | 3.295B |
December 31, 2021 | 1.991B |
December 31, 2020 | 1.37B |
Date | Value |
---|---|
December 31, 2019 | 496.00M |
December 31, 2018 | 454.08M |
December 31, 2017 | 410.46M |
December 31, 2016 | 274.72M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
496.00M
Minimum
2019
4.845B
Maximum
2023
2.399B
Average
1.991B
Median
2021
Research and Development Expense (Annual) Benchmarks
Merck & Co Inc | 30.53B |
Pfizer Inc | 10.68B |
Eli Lilly and Co | 9.313B |
Novavax Inc | 737.50M |
Regeneron Pharmaceuticals Inc | 4.439B |